| Bioactivity | CY 208-243 is a selective dopamine D1 receptor agonist which exhibits antiparkinsonian activity[1]. | ||||||||||||
| In Vivo | Pretreatment with CY 208-243 (2.5 mg/kg; s.c.) prevents the increase of DA release and metabolism induced by the D-1 antagonist, SCH 23390 (0.05 mg/kg; s.c.)[1]. Animal Model: | ||||||||||||
| Name | CY 208-243 | ||||||||||||
| CAS | 100999-26-6 | ||||||||||||
| Formula | C19H18N2 | ||||||||||||
| Molar Mass | 274.36 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Imperato A, et al. CY 208-243, a novel dopamine D-1 receptor agonist, fails to modify dopamine release in freely moving rats. Eur J Pharmacol. 1989 Jan 24;160(1):155-8. [2]. Temlett JA, et al. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206. |